Trial Profile
A Prospective, Single Arm Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Usability of Abaloparatide-sMTS in Postmenopausal Women With Low Bone Mineral Density
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Abaloparatide (Primary)
- Indications Postmenopausal osteoporosis
- Focus Pharmacokinetics
- Sponsors Radius Health Inc.
- 27 Feb 2021 Results published in the Clinical Drug Investigation.
- 04 May 2017 New trial record